ATE198710T1 - Neuartiges polypeptid mit einer inhibierenden aktivität gegen faktor xa - Google Patents

Neuartiges polypeptid mit einer inhibierenden aktivität gegen faktor xa

Info

Publication number
ATE198710T1
ATE198710T1 AT94914087T AT94914087T ATE198710T1 AT E198710 T1 ATE198710 T1 AT E198710T1 AT 94914087 T AT94914087 T AT 94914087T AT 94914087 T AT94914087 T AT 94914087T AT E198710 T1 ATE198710 T1 AT E198710T1
Authority
AT
Austria
Prior art keywords
polypeptide
novel polypeptide
activity against
inhibiting activity
against factor
Prior art date
Application number
AT94914087T
Other languages
English (en)
Inventor
Elisha P Zeelon
Moshe M Werber
Avigdor Levanon
Original Assignee
Bio Technology General Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Technology General Corp filed Critical Bio Technology General Corp
Application granted granted Critical
Publication of ATE198710T1 publication Critical patent/ATE198710T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT94914087T 1993-04-09 1994-04-08 Neuartiges polypeptid mit einer inhibierenden aktivität gegen faktor xa ATE198710T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4580593A 1993-04-09 1993-04-09
PCT/US1994/003871 WO1994023735A1 (en) 1993-04-09 1994-04-08 Novel polypeptide having factor xa inhibitory activity

Publications (1)

Publication Number Publication Date
ATE198710T1 true ATE198710T1 (de) 2001-02-15

Family

ID=21939985

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94914087T ATE198710T1 (de) 1993-04-09 1994-04-08 Neuartiges polypeptid mit einer inhibierenden aktivität gegen faktor xa

Country Status (14)

Country Link
EP (1) EP0696198B1 (de)
JP (1) JPH08511157A (de)
KR (1) KR960701649A (de)
AT (1) ATE198710T1 (de)
AU (1) AU682361B2 (de)
CA (1) CA2159218A1 (de)
DE (1) DE69426598T2 (de)
DK (1) DK0696198T3 (de)
ES (1) ES2155472T3 (de)
GR (1) GR3035722T3 (de)
IL (1) IL109259A0 (de)
NZ (1) NZ265507A (de)
PT (1) PT696198E (de)
WO (1) WO1994023735A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2158923B1 (de) 1998-08-06 2013-02-27 Mountain View Pharmaceuticals, Inc. Peg-uricase Konjugate und Verwendung davon
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
WO2008051178A2 (en) 2006-04-12 2008-05-02 Savient Pharmaceuticals, Inc. Purification of proteins with cationic surfactant
DK3321359T3 (da) 2005-04-11 2021-03-08 Horizon Pharma Rheumatology Llc Variante former af uratoxidase og anvendelse deraf
CN102807973A (zh) 2005-04-11 2012-12-05 萨文特医药公司 尿酸氧化酶的变体形式及其用途
RU2535038C2 (ru) 2009-06-25 2014-12-10 Криэлта Фармасьютикалз ЭлЭлСи Способы и наборы для прогнозирования риска инфузионных реакций и опосредованной антителами потери ответа при терапии пэгилированной уриказой с помощью мониторинга содержания мочевой кислоты в сыворотке крови
US8685462B1 (en) 2012-09-17 2014-04-01 Biopep Solutions, Inc. Whole, leech saliva product and applications thereof
EP3538135A4 (de) 2016-11-11 2020-07-29 Horizon Pharma Rheumatology LLC Kombinationstherapien von prednison- und uricase-molekülen und deren verwendung
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588587A (en) * 1983-03-01 1986-05-13 Pennsylvania Hospital Method of treatment to inhibit metastasis
DE58907266T2 (de) * 1988-06-11 1994-09-29 Ciba Geigy Ag Polypeptide mit einer die Koagulierung hemmenden Wirkung.
US4832849A (en) * 1988-06-16 1989-05-23 Merrell Dow Pharmaceuticals Inc. Extraction and purification of an anticoagulant principle from the south american leech, haementeria ghilianii
IL86856A0 (en) * 1988-06-24 1988-11-30 Yissum Res Dev Co Bovine xa factor and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
IL109259A0 (en) 1994-07-31
DK0696198T3 (da) 2001-08-06
WO1994023735A1 (en) 1994-10-27
NZ265507A (en) 1998-09-24
JPH08511157A (ja) 1996-11-26
KR960701649A (ko) 1996-03-28
EP0696198B1 (de) 2001-01-17
HK1013315A1 (en) 1999-08-20
DE69426598T2 (de) 2001-08-09
PT696198E (pt) 2001-07-31
EP0696198A4 (de) 1999-01-27
EP0696198A1 (de) 1996-02-14
CA2159218A1 (en) 1994-10-27
GR3035722T3 (en) 2001-07-31
AU6629194A (en) 1994-11-08
AU682361B2 (en) 1997-10-02
ES2155472T3 (es) 2001-05-16
DE69426598D1 (de) 2001-02-22

Similar Documents

Publication Publication Date Title
DE69426598D1 (de) Neuartiges polypeptid mit einer inhibierenden aktivität gegen faktor xa
PL309398A1 (en) Interferon containing therapeutic composition
HU9203137D0 (en) New growth regulating proteines and epithelines rich in cysteine and their production
DE69333626D1 (de) Verwendung von Adamantan Derivaten zur Herstellung eines Medikaments zur GLAUKOMBEHANDLUNG
GB9614967D0 (en) Surface treatment process
PT86381A (en) Molecular cloning and expression of human il-3
PL307258A1 (en) Peptides capable to block calcium canals with agelenopsis aperta
DE69330272D1 (de) 4-imidomethyl-1-[2'-phenyl-2-oxoethyl]-piperidine als serotonin-5ht2-antagonisten, ihre herstellung und therapeutische anwendung
EP0460072A4 (en) Human elastase inhibitor
DE69205154D1 (de) Verwendung von mindestens einem gereinigten peptid, welches durch kaseinhydrolyse hergestellt werden kann und opiataktivität hat, als aktiven bestandteil in der herstellung einer kosmetischen zusammensetzung.
MY128309A (en) Improvements relating to termite control
DE69004794D1 (de) Verwendung eines Polypeptids mit Interleukin 2-Aktivität zur Herstellung einer zur Behandlung von einfachen Pleurageschwüren bestimmten pharmazeutischen Zusammensetzung.
CA2093819A1 (en) Platelet adhesion inhibitor
Rawczynska-Englert et al. Staphylococcal endocarditis after valve replacement(9 years of experience).
Lekan CORONA TREATMENT AS AN ADHESION PROMOTER FOR UV-/EB-CURABLE COATINGS
EP0181524A3 (de) Lymphokin
UA9891A (uk) Склоформуючий інструмент
Ligabue The liming intervention: Technical problems and solutions adopted.]
AU3217889A (en) Production of insulin-like growth factor binding protein
CA2505487A1 (en) Levobupivacaine and its use as an anaesthetic in obstetrics
GB1498740A (en) Inhibiting bacterial growth in dental appliances
UA29617A (uk) Спосіб одержання протимікробного фітозасобу з інтерфероніндукуючою активністю
CA2173207A1 (en) Levobupivacaine and its use as an anaesthetic in patients having or disposed to depressed myocardial contractility
UA7184C2 (uk) Контактний спосіб зниження артеріального тиску за методикою шпортюк м.і.
AU110262S (en) Mitten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee